LL-37

Background

LL‑37 is the only known human cathelicidin antimicrobial peptide, generated by proteolytic cleavage of the C‑terminal region of the precursor protein hCAP18 (also termed CAMP). It is a 37‑amino‑acid, cationic, amphipathic α‑helical peptide beginning with two leucine residues, hence the designation LL‑37.[1][10] LL‑37 is expressed primarily by neutrophils and various epithelial cells (skin, respiratory, gastrointestinal, genitourinary), and its expression is inducible by infection, inflammation, vitamin D, and certain cytokines.[1][7]

Historically, cathelicidins were identified as a family of host‑defense peptides in mammals in the early 1990s; the human gene CAMP and its peptide product LL‑37 were subsequently characterized as key components of innate immunity with broad antimicrobial and immunomodulatory functions.[1][10] LL‑37 has since been implicated in wound repair, sepsis, antiviral defense, cardiovascular disease, and cancer biology, making it a widely studied host‑defense peptide and a template for multiple therapeutic analogs.[1][6][15]

Despite strong preclinical interest, LL‑37 itself is not approved as a drug in the US or EU; current development efforts focus on recombinant LL‑37 and modified fragments or formulations designed to retain antimicrobial and immunomodulatory activity with reduced cytotoxicity and improved stability.[1][4][10]

Mechanism of action

Antimicrobial and antiviral actions

LL‑37 exerts broad‑spectrum antimicrobial activity against Gram‑positive and Gram‑negative bacteria, fungi, some parasites, and numerous enveloped viruses.[1][7] As a cationic amphipathic peptide, LL‑37 interacts with negatively charged microbial membranes, inserts into lipid bilayers, and can form pores or disrupt membrane integrity, leading to rapid cell death.[1][8] Biophysical studies using phospholipid monolayers demonstrate that LL‑37 interacts differently with phosphatidylglycerol-, cardiolipin-, and other phospholipid‑rich membranes, consistent with preferential targeting of bacterial envelopes.[8]

LL‑37 also exhibits direct antiviral effects. In Venezuelan equine encephalitis virus (VEEV) models, LL‑37 binds viral particles, promotes their aggregation, and inhibits early stages of viral entry and replication in host cells, reducing viral RNA copies and titers in infected cultures.[3] Similar mechanisms (direct virion disruption and induction of an antiviral state) have been described for other viruses in preclinical studies.[1][3]

Immunomodulation and host defense

Beyond direct microbicidal activity, LL‑37 is a pleiotropic immunomodulator. It binds and neutralizes lipopolysaccharide (LPS) and other bacterial toxins, attenuating Toll‑like receptor–mediated inflammatory responses.[2][7] LL‑37 can act as a chemoattractant, promoting recruitment of neutrophils, monocytes, T cells, and mast cells, partly through interaction with formyl peptide receptor‑like 1 (FPRL1/FPR2) and other G‑protein–coupled receptors.[7][10]

LL‑37 modulates inflammasome activation and cell death pathways. In a murine cecal ligation and puncture (CLP) sepsis model, LL‑37 reduced macrophage pyroptosis, decreased IL‑1β release, and improved survival, indicating suppression of excessive inflammatory cell death.[2][14] It also enhances neutrophil extracellular trap (NET) formation and stimulates release of antimicrobial microvesicles (ectosomes), reinforcing host defense and bacterial clearance.[2][14]

LL‑37 influences epithelial and stromal cell biology, including promotion of cell migration, angiogenesis, and re‑epithelialization, contributing to wound healing.[11][13] In cardiovascular and cancer settings, LL‑37 modulates pathways related to atherosclerosis, thrombosis, cardiac hypertrophy, and tumor progression in a context‑dependent manner.[6][15]

Receptor and intracellular targets

Identified LL‑37 interaction partners include:

• FPR2/FPRL1 and other G‑protein–coupled receptors: mediate chemotaxis, calcium influx, and pro‑/anti‑inflammatory signaling.[7][10]
• Nucleic acid–sensing Toll‑like receptors (e.g., TLR9) via LL‑37–DNA complexes, facilitating uptake and modulating immune activation.[7]
• Various membrane phospholipids and glycosaminoglycans, which govern binding, internalization, and cytotoxicity.[8][9]

LL‑37 can be internalized, localize to cytoplasmic or nuclear compartments, and affect gene expression, though these mechanisms are incompletely characterized.[1][10]

Evidence summary

Antimicrobial and wound‑healing applications

Preclinical studies demonstrate potent anti‑biofilm and wound‑healing effects. In vitro and ex vivo models show that LL‑37 disrupts biofilms of multiple Gram‑positive and Gram‑negative pathogens and promotes keratinocyte migration and angiogenesis.[11][13] A comprehensive review on polymicrobial infected wounds summarizes LL‑37’s dual antimicrobial and wound‑repair activities and proposes it as a candidate for chronic wound therapy, though controlled clinical trials in humans remain limited.[11][13]

Nanoparticle‑based formulations have been developed to enhance pulmonary delivery. Cetyl palmitate–based lipid nanoparticles loaded with LL‑37 (~35–42 nm) were cytocompatible with human lung epithelial cells, preserved barrier function in an air–liquid interface model, prevented Pseudomonas aeruginosa biofilm formation, and disrupted early biofilms at lower peptide doses compared with free LL‑37.[5] This work was conducted in vitro without human subjects.[5]

Sepsis and systemic inflammation

In a murine CLP sepsis model, LL‑37 administration improved survival compared with untreated controls (exact group sizes vary by experiment but typically involve n≈10–15 mice per group).[2][14] LL‑37 reduced bacterial burden, decreased IL‑1β and other pro‑inflammatory cytokines, suppressed macrophage pyroptosis, and enhanced NET and ectosome release, highlighting multimodal protective effects.[2][14] These data are preclinical; there are no completed phase 2/3 sepsis trials with LL‑37.

Antiviral activity

In VEEV infection models, LL‑37 treatment significantly decreased genomic RNA copies and infectious virion titers for both the attenuated TC‑83 and virulent Trinidad Donkey strains in cell culture, with inhibitory effects most pronounced when LL‑37 was present during early entry stages.[3] These findings support direct antiviral and entry‑blocking mechanisms in vitro; in vivo antiviral efficacy has not yet been established in humans.

Cardiovascular and cancer biology

LL‑37 has been implicated in heart disease pathogenesis and protection. A recent review synthesizes animal and cell studies showing that LL‑37 can modulate atherosclerotic plaque development, thrombosis, inflammatory responses, and cardiac hypertrophy; engineered LL‑37 derivatives demonstrate cardioprotective or disease‑modifying effects in preclinical models.[6] However, interventional human data are lacking.

In oncology, LL‑37 exhibits context‑dependent functions, acting as a pro‑tumorigenic factor in some epithelial cancers (e.g., lung, ovarian) and an anti‑tumor peptide in others (e.g., colon).[15] The peptide influences proliferation, apoptosis, and angiogenesis through multiple signaling pathways. A review of LL‑37 in cancer underscores its potential as a therapeutic target or agent but emphasizes that evidence is largely preclinical, with no approved cancer indications.[15]

Biodistribution and pharmacokinetics

A SPECT/CT study in healthy mice using 67Ga‑labeled LL‑37 (~>20 µg) characterized systemic distribution after intravenous or subcutaneous administration.[9] Intravenous dosing led to rapid blood clearance with predominant hepatic uptake and transient lung distribution, whereas subcutaneous dosing showed two‑phase systemic absorption and primarily renal clearance, with uptake in lymphoid tissues (lymph nodes, spleen) for both routes.[9] These data provide the most direct in vivo pharmacokinetic insights available but are limited to animals.

Clinical and research uses

LL‑37 is best described as an investigational host‑defense peptide rather than an established therapeutic. Reported or proposed uses include:

• Infectious diseases and biofilms: topical or local administration for chronic wounds, diabetic foot ulcers, and device‑associated infections, primarily in preclinical or early exploratory clinical contexts.[11][13]
• Pulmonary infections: inhalable or nanoparticle‑encapsulated LL‑37 to treat resistant bacterial infections and biofilms in lung disease (e.g., P. aeruginosa), currently at in vitro and animal‑model stages.[5]
• Sepsis and systemic infection: systemic administration in animal sepsis models with improved survival; human trials are not yet established.[2][14]
• Cardiovascular disease: exploratory use of LL‑37‑derived peptides to modulate atherosclerosis, thrombosis, and cardiac remodeling in preclinical studies.[6]
• Cancer therapy: development of LL‑37 fragments or analogs with selective anti‑tumor activity, or strategies to inhibit LL‑37 where it appears pro‑tumorigenic; research remains preclinical.[15]

Human clinical trials of recombinant LL‑37 or analogs have been sporadically registered, but robust, large‑scale, peer‑reviewed phase 2/3 efficacy data are not yet available. Existing evidence is therefore predominantly preclinical or early phase.

Dosing context

Published work uses a wide range of experimental doses, reflecting research objectives rather than therapeutic regimens.

• In vitro antimicrobial and cytotoxicity studies often employ LL‑37 at 1–10 µM, a range associated with strong antimicrobial effects but also with cytotoxicity to human cells in some contexts.[7][10]
• In psoriatic lesions, local LL‑37 concentrations have been estimated at up to ~300 µM, while gingival crevicular fluid in periodontitis contains around 1 µM, illustrating physiologic/pathophysiologic exposure levels.[7]
• In the SPECT/CT mouse biodistribution study, exogenous LL‑37 was administered at just over 20 µg per animal intravenously or subcutaneously for imaging purposes.[9]
• In murine sepsis and infection models, LL‑37 has been administered systemically or locally in the low‑ to mid‑mg/kg range (exact dose and schedule vary across experiments), leading to improved survival or reduced pathogen burden.[2][14]

These dosing parameters are experimental and not validated therapeutic regimens for humans. No standardized or regulatory‑approved dosing scheme for LL‑37 exists.

Safety profile

LL‑37 exhibits a narrow therapeutic window in vitro, with antimicrobial and immunomodulatory actions overlapping with cytotoxic concentrations.[1][7][10]

• At 1–10 µM, LL‑37 is cytotoxic to various human cell types, including osteoblasts, vascular smooth muscle cells, periodontal ligament cells, neutrophils, airway epithelial cells, and T cells.[7][10]
• High local concentrations, such as those found in psoriatic skin (~300 µM), are associated with inflammation and tissue damage, suggesting that LL‑37 overexpression may contribute to inflammatory and autoimmune pathology.[7][10]

Preclinical animal studies indicate potential adverse effects related to:

• Membrane disruption and cytotoxicity in non‑target tissues at higher systemic exposures.[1][10]
• Pro‑inflammatory effects, including amplification of certain immune responses and possible promotion of thrombosis or atherosclerosis in specific contexts, as reviewed in cardiovascular disease models.[6]
• Cancer biology, where LL‑37 can promote tumor growth, angiogenesis, and metastasis in some malignancies, raising concerns about systemic, long‑term administration.[15]

Clinical safety data in humans are limited and largely derived from small or early‑phase studies using recombinant LL‑37 or analogs. Reported adverse events are mainly local injection‑site or application‑site reactions and transient inflammatory responses, but systematic safety characterization is incomplete.

Given these findings, LL‑37 and its analogs are typically developed as localized or targeted therapies (e.g., topical, inhaled, nanoparticle‑encapsulated) to minimize systemic exposure and off‑target toxicity.[1][5]

Contraindications and precautions (theoretical)

Formal contraindications have not been defined by regulatory agencies. Based on mechanistic and preclinical data, potential risk groups may include:

• Patients with psoriasis or other LL‑37‑driven inflammatory diseases, where additional LL‑37 might exacerbate pathology.[7]
• Individuals with cancers in which LL‑37 is pro‑tumorigenic.[15]
• Conditions with heightened risk of thrombosis or atherosclerosis, pending further clarification of LL‑37’s cardiovascular effects.[6]

These concerns remain theoretical until more extensive human safety data become available.

Regulatory status

As of current evidence, LL‑37 is not approved as a medicinal product by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any indication. Contemporary reviews describe LL‑37 and its derivatives as promising investigational agents whose translation is limited by proteolytic instability, cytotoxicity, and manufacturing challenges.[1][4][10]

LL‑37‑based products are being explored in academic and early‑stage industrial research programs for infectious diseases, wound healing, cardiovascular disorders, and cancer, but no LL‑37 drug has completed the regulatory approval process in the US or EU.[1][4][6][15]

Current development emphasizes modified LL‑37 fragments and advanced delivery systems rather than the unmodified peptide, with the goal of achieving a favorable balance between antimicrobial efficacy, immunomodulation, and safety.[1][5][10] LL‑37 should therefore be regarded as a research‑stage host‑defense peptide with substantial preclinical support but limited clinical validation.